HRT after 60: starting and continuing are different decisions
Beginning systemic menopausal hormone therapy after 60 or more than 10 years after menopause has a different average benefit–risk profile from reviewing a regimen already helping someone. Age alone is neither an automatic start nor an automatic stop rule.
Starting systemic menopause hormone therapy after age 60 is not the same decision as continuing a regimen that began earlier. The Menopause Society says the average benefit–risk balance is less favorable when therapy is first started after 60 or more than 10 years after menopause, because absolute risks of several outcomes rise with age and time. It also says an existing regimen need not be stopped solely because a birthday passes. Either decision needs a current indication, product-specific review and periodic reassessment—not an age cutoff applied in isolation.123
Two paths meet at the same birthday
The phrase “HRT after 60” may describe a first prescription at 62, a person who started at 51 and is considering continuing at 62, or someone restarting after years away. Those histories cannot be collapsed into a single yes/no answer. The clinical question is not only age; it includes time since menopause, symptoms or other goal, exact formulation, uterine status, medical history and alternatives.1
| Situation | Question to assess | Common shortcut to avoid |
|---|---|---|
| First start after 60 | What is the indication, and how do current risks and alternatives compare? | Assuming outcomes from people who started closer to menopause apply unchanged |
| Continuing an established regimen | Does the benefit still matter, and have risks, preferences or products changed? | Stopping automatically at 60 or 65 |
| Restarting after a gap | How long was the gap and what is the current reason to restart? | Calling a new decision mere continuation |
| Changing route or formulation | What exact new product and label are proposed? | Assuming all estrogen products have one shared risk estimate |
The Menopause Society’s position statement is careful with its wording. “Less favorable” is a population-average comparison, not a statement that treatment is prohibited or that a particular person will have a complication. Conversely, “not routinely discontinue” is not an instruction to continue forever. ACOG’s patient guidance recommends discussing whether to continue at least yearly.123
What a continuation review should establish
A review begins with the reason treatment was started and whether that reason still applies. Persistent vasomotor symptoms and quality-of-life effects can matter; a vague “anti-aging” objective is not the same clinical indication. The prescriber should confirm the exact current estrogen and, where relevant, progesterone or progestin product; route, dose and schedule; and whether the uterus is present. The estradiol patch-versus-pill guide explains why route changes the evidence question without declaring a universal winner.
Next, ask what has changed since the last review: new diagnoses, medicines, bleeding, cardiovascular or clot history, smoking, breast history and personal preferences. Product labels and guideline recommendations have scope; they cannot be applied accurately without this updated history. A practice should document a follow-up date and identify who handles new symptoms between visits. This is a shared-decision process with a licensed clinician, not a do-it-yourself continuation test.
If bone health is the stated reason, ask whether the product’s FDA-labeled indication is prevention of postmenopausal osteoporosis, whether established osteoporosis has been assessed, and who owns fracture-risk care. The bone-prevention-versus-treatment guide separates those questions. Do not assume a hormone-therapy listing means the practice manages diagnosed osteoporosis.
What a later first start should establish
A first start after 60 needs a clear, current objective and an honest discussion of why this approach is being considered now. The Society’s timing statement should be part of that conversation, along with individual risks, nonhormonal options and the exact product’s label. The clinician should explain what success would mean for the stated goal, what side effects or new symptoms call for review, and when the first check-in will occur. Nothing in a consumer article can supply a personal threshold for starting or an individualized treatment plan.1
Avoid using a regulatory headline as an all-clear for a personal decision. A label change does not replace a review of the exact product and current risks, or create one age rule for every patient. The label-change explainer covers that separate issue.
Choose a provider who can explain the branch
It is a positive sign when a consultation distinguishes new initiation from ongoing use before quoting a generic “safe until 65” or “stop at 60” slogan. It should identify the clinician who will revisit the decision and coordinate other relevant care. Use Treomark’s hormone-therapy provider discovery as a starting point, then ask the practice how it conducts the specific review your history calls for.
Sources
- The Menopause Society. The 2022 hormone therapy position statement. Initiation after age 60 or more than 10 years since menopause has a less favorable average benefit–risk ratio; continuation needs periodic reassessment. Accessed .
- The Menopause Society. The Menopause Society releases updated position statement on hormone therapy. Society clarification that treatment need not be routinely stopped solely because of age 60 or 65. Accessed .
- American College of Obstetricians and Gynecologists. Hormone Therapy for Menopause. Patient guidance to revisit hormone-therapy benefits and risks with a clinician at least yearly. Accessed .